Measurement of leptin and soluble leptin receptor levels in patients with endometrial hyperplastic processes

Abstract

Objective. To measure leptin and soluble leptin receptor levels in patients with endometrial hyperplastic processes.Materials and methods. 90 patients were included in the study, 70 with hyperplastic endometrial processes made up the main group, 20 with morphologically normal endometrium were included in the comparison group. The concentration of leptin and the soluble leptin receptor in the blood serum was measured by the method of enzyme immunoassay, the clinical and anamnestic characteristics of the disease were studied Results. There were no significant differences between the groups when comparing serum leptin levels: in the study group, the hormone level was 6,01 (3,64;7,50) ng/ml, in the comparison group — 6,44 (3,55;10,11) ng/ml (z = 0,61, p = 0,54). The level of soluble leptin receptor was significantly lower in patients in the main group and was 8531 (5697; 15895) ng/ml, and 16181 (10696; 20251) ng/ml in the comparison group (z = 2.614, p = 0.008).Conclusion. Patients with endometrial hyperplastic processes are characterized by a decreased level of the soluble leptin receptor, whereas a leptin level has no significant differences compared to those in patients without endometrial pathology. The identified condition causes a defect in the signal transmission from the leptin receptor and a decrease in the hormone transport, leading to a disruption of the biological action of leptin. The established level of soluble leptin receptor < 14769 pg/ml, in combination with ultrasound examination, will increase the efficiency of diagnostic measures to detect endometrial hyperplastic processes.